Maravai Lifesciences Holdings (MRVI) Cash from Operations (2020 - 2026)
Maravai Lifesciences Holdings (MRVI) posted quarterly Cash from Operations of 8665000.0 for Q1 2026, up 192.28% year-over-year from 2964632.9 in Q1 2025, and up 138.06% quarter-over-quarter from 22768000.0 in Q4 2025.
Maravai Lifesciences Holdings (MRVI) Cash from Operations (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' Cash from Operations history runs 7 years deep, the most recent figure standing at 8665000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 192.28% year-over-year to 8665000.0; the TTM figure through Mar 2026 stood at 39518000.0 (down 704.07% YoY), while the FY2025 annual figure was 57573000.0, down 871.24% from the prior year.
- Cash from Operations for Q1 2026 stood at 8665000.0, up from 22768000.0 in the prior quarter.
- The five-year high for Cash from Operations was 164279000.0 in Q2 2022, with the low at 22768000.0 in Q4 2025.
- The 5-year median for Cash from Operations is 13136000.0 (2024), against an average of 36515176.47.
- The sharpest annual moves came in 2022 and 2024: Cash from Operations jumped 323.48% in 2022, then plunged 287.91% in 2024.
- Maravai Lifesciences Holdings' Cash from Operations stood at 99335000.0 in 2022, then plunged by 92.16% to 7790000.0 in 2023, then slumped by 287.91% to 14638000.0 in 2024, then plunged by 55.54% to 22768000.0 in 2025, then surged by 138.06% to 8665000.0 in 2026.
- Business Quant data shows MRVI's Cash from Operations at 8665000.0 in Q1 2026, 22768000.0 in Q4 2025, and 15150000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -387.32 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 462.82 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -1.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 728.46 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 326.72 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Maravai Lifesciences Holdings | 1.48 Bn | 1.56 Bn | 20.65 Mn | 3.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.99 Mn |
| Jun 30, 2026 | 3.99 Mn |
| Mar 31, 2026 | 8.67 Mn |
| Mar 31, 2026 | 8.67 Mn |
| Dec 31, 2025 | -22.77 Mn |
| Dec 31, 2025 | -22.77 Mn |
| Sep 30, 2025 | -15.15 Mn |
| Sep 30, 2025 | -15.15 Mn |
| Jun 30, 2025 | -10.27 Mn |
| Jun 30, 2025 | -10.27 Mn |
| Mar 31, 2025 | -9.39 Mn |
| Mar 31, 2025 | -9.39 Mn |
| Dec 31, 2024 | -14.64 Mn |
| Dec 31, 2024 | -14.64 Mn |
| Sep 30, 2024 | 13.14 Mn |
| Sep 30, 2024 | 13.14 Mn |
| Jun 30, 2024 | 17.43 Mn |
| Jun 30, 2024 | 17.43 Mn |
| Mar 31, 2024 | -8.47 Mn |
| Mar 31, 2024 | -8.47 Mn |